Pfizer moved 0.1% this afternoon session, trading between a high of $31.075 and a low of $30.51 per share. Yesterday the stock finished at $30.56 per share, compared to an average analyst target price of $38.67.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The large-cap biotechnology: pharmaceutical preparations company is based in the United States, and over the last twelve months it has returned a dividend yield of 5.3%. Pfizer has trailing twelve months earnings per share (EPS) of 3.76, which at today's prices amounts to a price to earnings (P/E) ratio of 8.1.
Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of -2.29. Usually a PEG ratio between 0 and 1 indicates a potentially undervalued company.
Overview of the Company's Gross Margins:
| Date Reported | Revenue ($ k) | Cost of Revenue ($ k) | Gross Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 105,685,000 | 23,835,000 | 77 | -97.85 |
| 2022 | -987,000 | 34,344,000 | 3579 | 5672.58 |
| 2021 | 81,288,000 | 30,821,000 | 62 | -22.5 |
| 2020 | 41,651,000 | 8,484,000 | 80 | 0.0 |
| 2019 | 40,905,000 | 8,054,000 | 80 | 2.56 |
| 2018 | 40,825,000 | 8,987,000 | 78 |
At 659.3%, Pfizer's average gross margins are wider than the 60.94% average of its industry peer group, which suggests that the firm might have a competitive advantage.
